Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received an average rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year […]
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received an average rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year […]
